Facebook
Linkedin
Twitter
Industries
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Resource Center
Resources
Press Releases
Search
Tuesday, November 5, 2024
Facebook
Linkedin
Twitter
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
ReadMagazine
Industries
All
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
Digital Transformation Driving the Food Industry
Revenova and SMC³ Boost LTL Partnership for Enhanced Digitization
SpartanNash Welcomes Djouma Barry as SVP and CRO
Boston Scientific to Acquire Cortex, Inc.
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Resource Center
Resources
Press Releases
Home
Tags
Phase 2 IDEAL Study
Phase 2 IDEAL Study
Biotechnology
Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis
PR Newswire
-
April 27, 2022
Protagonist Therapeutics announced topline results from the Phase 2 IDEAL study evaluating PN-943 in patients with moderate-to-severe ulcerative colitis (UC). Also Read: Glass Lewis Proxy...
0
Fans
Like
3,912
Followers
Follow
0
Subscribers
Subscribe
Hot Topics
Digital Transformation Driving the Food Industry
Revenova and SMC³ Boost LTL Partnership for Enhanced Digitization
SpartanNash Welcomes Djouma Barry as SVP and CRO
Load more
